Author:
Amini Mahin,Moradinazar Mahdi,Rajati Fatemeh,Soofi Moslem,Sepanlou Sadaf G.,Poustchi Hossein,Eghtesad Sareh,Moosazadeh Mahmood,Harooni Javad,Aghazadeh-Attari Javad,Fallahi Majid,Fattahi Mohammad Reza,Ansari-Moghaddam Alireza,Moradpour Farhad,Nejatizadeh Azim,Shahmoradi Mehdi,Mansour-Ghanaei Fariborz,Ostadrahimi Alireza,Ahmadi Ali,Khaledifar Arsalan,Saghi Mohammad Hossien,Saki Nader,Mohebbi Iraj,Homayounfar Reza,Farjam Mojtaba,Nadimi Ali Esmaeili,Kahnooji Mahmood,Pourfarzi Farhad,Zamani Bijan,Rezaianzadeh Abbas,Johari Masoumeh Ghoddusi,Mirzaei Masoud,Dehghani Ali,Motlagh Seyed Fazel Zinat,Rahimi Zahra,Malekzadeh Reza,Najafi Farid
Abstract
Abstract
Background
Elevated blood pressure is associated with cardiovascular disease, stroke and chronic kidney disease. In this study, we examined the socioeconomic inequality and its related factors in prevalence, Awareness, Treatment and Control (ATC) of hypertension (HTN) in Iran.
Method
The study used data from the recruitment phase of The Prospective Epidemiological Research Studies in IrAN (PERSIAN). A sample of 162,842 adults aged > = 35 years was analyzed. HTN was defined according to the Joint National Committee)JNC-7(. socioeconomic inequality was measured using concentration index (Cn) and curve.
Results
The mean age of participants was 49.38(SD = ± 9.14) years and 44.74% of the them were men. The prevalence of HTN in the total population was 22.3%(95% CI: 20.6%; 24.1%), and 18.8%(95% CI: 16.8%; 20.9%) and 25.2%(95% CI: 24.2%; 27.7%) in men and women, respectively. The percentage of awareness treatment and control among individuals with HTN were 77.5%(95% CI: 73.3%; 81.8%), 82.2%(95% CI: 70.2%; 81.6%) and 75.9%(95% CI: 70.2%; 81.6%), respectively. The Cn for prevalence of HTN was -0.084. Two factors, age (58.46%) and wealth (32.40%), contributed most to the socioeconomic inequality in the prevalence of HTN.
Conclusion
The prevalence of HTN was higher among low-SES individuals, who also showed higher levels of awareness. However, treatment and control of HTN were more concentrated among those who had higher levels of SES, indicating that people at a higher risk of adverse event related to HTN (the low SES individuals) are not benefiting from the advantage of treatment and control of HTN. Such a gap between diagnosis (prevalence) and control (treatment and control) of HTN needs to be addressed by public health policymakers.
Funder
The Iranian Ministry of Health and Medical Education has contributed to the funding used in the PERSIAN Cohort through Grant no
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference53 articles.
1. World Health Organization. The World Bank. Tracking universal health coverage: first global monitoring report. 2015.
2. UN General Assembly. Transforming our world: the 2030 agenda for sustainable development. 2015, A/RES/70/1. Available at: https://www.refworld.org/docid/57b6e3e44.html. Accessed 31 May 2022.
3. Collins R, Peto R, MacMahon S, Godwin J, Qizilbash N, Hebert P, et al. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. The Lancet. 1990;335(8693):827–38.
4. Van Gaal L. Mechanisms linking obesity with cardiovascular disease. Diabetes, Obesity and Metabolism. 2010;12. https://www.researchgate.net/publication/295678895_Mechanisms_linking_obesity_with_cardiovascular_disease/citation/download.
5. Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA. 2012;307(12):1273–83.